{"id":27826,"date":"2022-08-05T11:43:21","date_gmt":"2022-08-05T09:43:21","guid":{"rendered":"https:\/\/www.ipsen.com\/?p=27826"},"modified":"2024-05-21T11:12:33","modified_gmt":"2024-05-21T09:12:33","slug":"ilc-2022-parlons-de-la-pbc","status":"publish","type":"post","link":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/","title":{"rendered":"ILC 2022 : parlons de la CBP"},"content":{"rendered":"\n

L\u2019International Liver Congress <\/em>(ILC)1<\/sup> est un \u00e9v\u00e9nement cl\u00e9 \u00e0 l\u2019occasion duquel les professionnels se r\u00e9unissent pour discuter de la prise en charge des pathologies du foie et des efforts de recherche sur ces maladies. Apr\u00e8s plusieurs \u00e9ditions virtuelles, il \u00e9tait particuli\u00e8rement appr\u00e9ciable de pouvoir interagir, discuter et d\u00e9battre en pr\u00e9sentiel cette ann\u00e9e.<\/p>\n\n\n\n

L\u2019un des principaux sujets de mes travaux cliniques et universitaires est la cholangite biliaire primitive (PBC), une maladie du foie dite \u00ab rare \u00bb qui repr\u00e9sente un fardeau consid\u00e9rable pour les patients, avec notamment un risque constant de d\u00e9velopper une cirrhose. La PBC est une pathologie moins fr\u00e9quente que de nombreuses autres maladies du foie (elle concerne une femme de plus de 40 ans sur 1 000)2<\/sup>. Des congr\u00e8s internationaux dynamiques tels que l\u2019ILC nous permettent donc de sensibiliser les professionnels n\u2019ayant pas de connaissances sp\u00e9cialis\u00e9es sur le diagnostic, la prise en charge et la surveillance de cette maladie.<\/p>\n\n\n\n

Le symposium \u00ab Current challenges in Primary Biliary Cholangitis: Debating the care odyssey \u00bb<\/em>, parrain\u00e9 par divers acteurs de l\u2019industrie, \u00e9tait une belle opportunit\u00e9 d\u2019\u00e9changer, de s\u2019informer et de diffuser des connaissances sur la PBC. Cet \u00e9v\u00e9nement a permis de mettre en lumi\u00e8re diff\u00e9rentes facettes de la PBC vis-\u00e0-vis des cliniciens et patients. J\u2019ai \u00e9t\u00e9 invit\u00e9 par Ipsen avec deux coll\u00e8gues \u00e9galement experts de la PBC, les Professeurs Cynthia Levy (\u00c9tats-Unis) et David Jones (Royaume-Uni), pour d\u00e9battre sur la question de savoir si le diagnostic tardif de la PBC repr\u00e9sente le plus grand d\u00e9fi de cette pathologie. Nous partagions tous le m\u00eame point de vue, s\u2019agissant notamment d\u2019am\u00e9liorer la qualit\u00e9 des soins des patients atteints de PBC en identifiant les aspects de la maladie qui ont un impact sur leur qualit\u00e9 de vie.<\/p>\n\n\n\n

Il est clairement ressorti des discussions qu\u2019un diagnostic rapide est la cl\u00e9 d\u2019une prise en charge efficace de la PBC, d\u2019autant plus que la maladie peut progresser jusqu\u2019\u00e0 un point o\u00f9 la r\u00e9ponse au traitement devient moins probable. N\u00e9anmoins, il a \u00e9galement \u00e9t\u00e9 \u00e9voqu\u00e9, parmi les contre-arguments, que le diagnostic ne repr\u00e9sentait pas le seul besoin non satisfait dans la PBC. En l\u2019absence de traitements efficaces permettant de modifier l\u2019\u00e9volution de la maladie tout en traitant les sympt\u00f4mes, la prise en charge de cette maladie peut \u00eatre difficile. La PBC doit \u00eatre correctement diagnostiqu\u00e9e \u00e0 un stade pr\u00e9coce, toutefois la r\u00e9ussite du diagnostic ne doit pas occulter la n\u00e9cessit\u00e9 d\u2019un traitement efficace chez les patients \u00e0 haut risque d\u00e9j\u00e0 identifi\u00e9s. En outre, le contr\u00f4le des sympt\u00f4mes et la qualit\u00e9 de vie sont deux aspects tout aussi importants qui devraient \u00eatre pris en compte dans la mise au point de nouveaux traitements ainsi que la prise de d\u00e9cisions relatives \u00e0 la prise en charge.<\/p>\n\n\n\n

Le d\u00e9bat s\u2019est orient\u00e9 vers de nombreux aspects cliniques des soins des patients atteints de PBC. La prise en charge de la PBC est de plus en plus dynamique ; de nouvelles innovations pharmacologiques sont en cours d\u00e9veloppement, et notre pratique doit s\u2019adapter \u00e0 ces changements3\u20135<\/sup>. L\u2019ILC est une excellente occasion d\u2019ouvrir le dialogue avec les cliniciens du monde entier \u00e0 ce sujet. Gr\u00e2ce \u00e0 ces \u00e9changes, nous continuons \u00e0 nous rapprocher de l\u2019objectif d\u2019apporter les meilleurs soins \u00e0 chaque patient, quel que soit l\u2019endroit o\u00f9 il vit.<\/p>\n\n\n\n

La PBC et les maladies h\u00e9patiques de type cholestase qui sont associ\u00e9es ont \u00e9t\u00e9 d\u2019importants sujets de discussion tout au long du congr\u00e8s, avec diverses pr\u00e9sentations de travaux de recherche sur les composantes inflammatoires et cholestatiques de cette maladie, des outils d\u2019\u00e9valuation de la qualit\u00e9 de vie sp\u00e9cifiques \u00e0 la PBC et des pratiques de reporting de donn\u00e9es sur les soins bas\u00e9es sur la population de patients. D\u2019autres sujets essentiels ont \u00e9t\u00e9 abord\u00e9s, comme les cibles de traitement et les m\u00e9thodes que nous pouvons adopter pour fournir un traitement personnalis\u00e9 aux patients atteints de cette maladie h\u00e9patique auto-immune chronique, tout au long de leur vie. L\u2019identification des patients \u00e0 haut risque, ayant eu une r\u00e9ponse insuffisante au traitement de r\u00e9f\u00e9rence et qui auront besoin d\u2019un traitement de deuxi\u00e8me ligne ult\u00e9rieurement, reste \u00e9galement un d\u00e9fi. Enfin, le sujet controvers\u00e9 du syndrome de chevauchement reste un th\u00e8me de discussion central dans la PBC. Nous esp\u00e9rons n\u00e9anmoins que lorsque nous serons mieux en mesure de traiter les patients atteints de PBC avec des th\u00e9rapies plus efficaces, plus t\u00f4t dans leur maladie, ils seront moins nombreux \u00e0 pr\u00e9senter des caract\u00e9ristiques de chevauchement dans l\u2019\u00e9volution de leur maladie.<\/p>\n\n\n\n

Nous entrons dans une nouvelle \u00e8re, o\u00f9 une meilleure compr\u00e9hension de la maladie, en parall\u00e8le des avanc\u00e9es th\u00e9rapeutiques, nous permettra de proposer des interventions plus pertinentes aux patients atteints de PBC.<\/p>\n\n\n\n

Prof. Gideon Hirschfield<\/p>\n\n\n\n

Universit\u00e9 de Toronto, Canada<\/p>\n\n\n\n

    \n
  1. International Liver Congress 2022. https:\/\/easl.eu\/event\/international-liver-congress-2022\/. Accessed August 2022.<\/li>\n\n\n\n
  2. Hirschfield GM et al J Hepatol 2017;67:145\u2013172<\/li>\n\n\n\n
  3. Lindor KD et al Hepatology<\/em> 2022;75:1012\u20131013<\/li>\n\n\n\n
  4. Louie JS et al Clinical Liver Disease <\/em>2020;15:100\u2013104<\/li>\n\n\n\n
  5. Benedetta T et al J Autoimmunity <\/em>2019;105<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    L\u2019International Liver Congress (ILC)1 est un \u00e9v\u00e9nement cl\u00e9 \u00e0 l\u2019occasion duquel les professionnels se r\u00e9unissent pour discuter de la prise<\/p>\n","protected":false},"author":9,"featured_media":19184,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[138],"tags":[150],"class_list":["post-27826","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-rare-diseases","tag-rare-disease","entry"],"acf":[],"yoast_head":"\nParlons de la CBP<\/title>\n<meta name=\"description\" content=\"Prenez part aux \u00e9changes sur la CBP \u00e0 l\u2019occasion de l\u2019ILC 2022. L\u2019initiative d\u2019Ipsen vise \u00e0 sensibiliser et \u00e0 accompagner les personnes atteintes de cette maladie rare.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Parlons de la CBP\" \/>\n<meta property=\"og:description\" content=\"Prenez part aux \u00e9changes sur la CBP \u00e0 l\u2019occasion de l\u2019ILC 2022. L\u2019initiative d\u2019Ipsen vise \u00e0 sensibiliser et \u00e0 accompagner les personnes atteintes de cette maladie rare.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-05T09:43:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-21T09:12:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"konstantinoskampanos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"konstantinoskampanos\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/\"},\"author\":{\"name\":\"konstantinoskampanos\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/caf513ba91f9535b6b2d8a79d95764c5\"},\"headline\":\"ILC 2022 : parlons de la CBP\",\"datePublished\":\"2022-08-05T09:43:21+00:00\",\"dateModified\":\"2024-05-21T09:12:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/\"},\"wordCount\":892,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg\",\"keywords\":[\"Rare disease\"],\"articleSection\":[\"Rare Disease\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/\",\"name\":\"Parlons de la CBP\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg\",\"datePublished\":\"2022-08-05T09:43:21+00:00\",\"dateModified\":\"2024-05-21T09:12:33+00:00\",\"description\":\"Prenez part aux \u00e9changes sur la CBP \u00e0 l\u2019occasion de l\u2019ILC 2022. L\u2019initiative d\u2019Ipsen vise \u00e0 sensibiliser et \u00e0 accompagner les personnes atteintes de cette maladie rare.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg\",\"width\":683,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ILC 2022 : parlons de la CBP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/caf513ba91f9535b6b2d8a79d95764c5\",\"name\":\"konstantinoskampanos\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/461d8aaa3dc000968b96f9df6ebfd0f045990cabf9f91de7f7dc4b9542e2adc8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/461d8aaa3dc000968b96f9df6ebfd0f045990cabf9f91de7f7dc4b9542e2adc8?s=96&d=mm&r=g\",\"caption\":\"konstantinoskampanos\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Parlons de la CBP","description":"Prenez part aux \u00e9changes sur la CBP \u00e0 l\u2019occasion de l\u2019ILC 2022. L\u2019initiative d\u2019Ipsen vise \u00e0 sensibiliser et \u00e0 accompagner les personnes atteintes de cette maladie rare.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/","og_locale":"fr_FR","og_type":"article","og_title":"Parlons de la CBP","og_description":"Prenez part aux \u00e9changes sur la CBP \u00e0 l\u2019occasion de l\u2019ILC 2022. L\u2019initiative d\u2019Ipsen vise \u00e0 sensibiliser et \u00e0 accompagner les personnes atteintes de cette maladie rare.","og_url":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/","og_site_name":"Global","article_published_time":"2022-08-05T09:43:21+00:00","article_modified_time":"2024-05-21T09:12:33+00:00","og_image":[{"width":683,"height":1024,"url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg","type":"image\/jpeg"}],"author":"konstantinoskampanos","twitter_card":"summary_large_image","twitter_creator":"@ipsengroup","twitter_site":"@ipsengroup","twitter_misc":{"Written by":"konstantinoskampanos","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/"},"author":{"name":"konstantinoskampanos","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/caf513ba91f9535b6b2d8a79d95764c5"},"headline":"ILC 2022 : parlons de la CBP","datePublished":"2022-08-05T09:43:21+00:00","dateModified":"2024-05-21T09:12:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/"},"wordCount":892,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg","keywords":["Rare disease"],"articleSection":["Rare Disease"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/","url":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/","name":"Parlons de la CBP","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg","datePublished":"2022-08-05T09:43:21+00:00","dateModified":"2024-05-21T09:12:33+00:00","description":"Prenez part aux \u00e9changes sur la CBP \u00e0 l\u2019occasion de l\u2019ILC 2022. L\u2019initiative d\u2019Ipsen vise \u00e0 sensibiliser et \u00e0 accompagner les personnes atteintes de cette maladie rare.","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#primaryimage","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg","width":683,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/actualites\/rare-diseases-fr\/ilc-2022-parlons-de-la-pbc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"ILC 2022 : parlons de la CBP"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/caf513ba91f9535b6b2d8a79d95764c5","name":"konstantinoskampanos","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/461d8aaa3dc000968b96f9df6ebfd0f045990cabf9f91de7f7dc4b9542e2adc8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/461d8aaa3dc000968b96f9df6ebfd0f045990cabf9f91de7f7dc4b9542e2adc8?s=96&d=mm&r=g","caption":"konstantinoskampanos"}}]}},"jetpack_featured_media_url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/Gideon-Headshot-683x1024-1.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/27826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/comments?post=27826"}],"version-history":[{"count":4,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/27826\/revisions"}],"predecessor-version":[{"id":56525,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/posts\/27826\/revisions\/56525"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/19184"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=27826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=27826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=27826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}